Cogent Biosciences
COGT
69 hedge funds and large institutions have $294M invested in Cogent Biosciences in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 19 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
2.06% more ownership
Funds ownership: 92.68% → 94.74% (+2.1%)
0% more funds holding
Funds holding: 69 → 69 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
3% less capital invested
Capital invested by funds: $303M → $294M (-$9.54M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.8M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.36M |
| 4 |
DM
Deerfield Management
New York
|
+$5.08M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| 2 |
Millennium Management
New York
|
-$6.73M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.7M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.96M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.46M |
COGT Hedge Fund Activity: Q2 2021 in Review
69 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2021, worth a combined $294M — down 3.1% from $303M a quarter earlier.
Fund positioning in COGT was balanced in Q2 2021: 19 funds opened new positions, 19 closed out, 18 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $17.8M. The largest seller was Citadel Advisors, exiting entirely with an estimated $11.1M sold.
- 69 institutional investors held Cogent Biosciences (COGT) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $294M of Cogent Biosciences stock for Q2 2021, down 3.1% quarter-over-quarter.
- 19 funds opened new Cogent Biosciences positions in Q2 2021 and 19 closed out, a net change of 0 holders.
- The largest Cogent Biosciences buyer in Q2 2021 was BlackRock, an estimated $17.8M added.
- The largest Cogent Biosciences seller in Q2 2021 was Citadel Advisors, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2021.